Location of Repository

Computational Analyses of Protein-Ligand Interactions

By Kamran Haider


Protein-ligand interactions have a central role in all processes in living systems. A comprehensive understanding of protein interactions with small molecules is of great interest as it provides opportunities for understanding protein function and therapeutic intervention. The major aims of this thesis were to characterise protein-ligand interactions from databases of crystal structures and to apply molecular modelling techniques for accurate prediction of binding modes of molecular fragments in protein binding sites. \ud The first aspect of the project was the analysis of hydrogen bond donors and acceptors in 187 protein-ligand complexes of resolution 2.5Å or better. The results showed that an extremely small fraction of them were not explicitly hydrogen bonded, with the hydrogen bond criterion of donor-acceptor distance ≤ 3.5 Å and H-bond angle of ≥ 90°. It was also noticed that a vast majority of such cases were explicable on the basis of weak interactions and weak donor/acceptor strength. The results were consistent with reported observations for buried protein regions. In a series of docking calculations, the fraction of lost hydrogen bonds was evaluated as a discriminator of good versus bad docking poses. Docking and scoring with a standard program, rDock, did not create incorrect poses with missing hydrogen bonds to an extent that would make lost hydrogen bonds a strong discriminator. The second aspect of the research is related to weak (CH-π and XH-π, X=N,O,S) interactions. In a survey of IsoStar, a database of protein-ligand interactions, subtle differences were noticed in geometric parameters of π interactions involving different types of ligand aromatic rings with strong and weak donor groups in binding sites. The results supported the hypothesis that energetically favourable interaction patterns are more frequent when there are electron-donating substituents attached to the aromatic ring. Finally, the applicability of a modelling technique, multiple copy simultaneous search, in terms of predicting energetically favourable poses of solvents and fragments in target binding sites, was explored in detail. Several factors such as re-scoring with a better scoring function, use of multiple receptor structures and good quality prediction of water binding sites led to a robust protocol for high quality predictions of fragment binding in test datasets

Publisher: Chemistry (York)
Year: 2010
OAI identifier: oai:etheses.whiterose.ac.uk:1242

Suggested articles



  1. (2000). 4-Anilino-6,7-dialkoxyquinolime-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.
  2. (2005). 4-Aryl-1,2,3-triazole: A novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo.
  3. (1995). A 2nd Generation ForceField for the Simulation of Proteins, Nucleic-Acids, and Organic-Molecules.
  4. (2002). A C-H...O Hydrogen Bond Stabilized Polypeptide Chain Reversal Motif at the C Terminus of Helices in Proteins.
  5. (1996). A comprehensive analytical treatment of continuum electrostatics.
  6. (1985). A Computational-Procedure For Determining Energetically Favorable Binding-Sites On Biologically Important Macromolecules.
  7. (2007). A decade of fragment-based drug design: strategic advances and lessons learned. Nature Reviews Drug Discovery
  8. (1996). A fast flexible docking method using an incremental construction algorithm.
  9. (1999). A general and fast scoring function for proteinligand interactions: A simplified potential approach.
  10. (2010). A Medicinal Chemist's Guide to Molecular Interactions.
  11. (2002). A new test set for validating predictions of protein-ligand interaction. ProteinsStructure Function and Genetics
  12. Accelrys Discovery Studio 2.5,
  13. (2000). Advances in surface plasmon resonance biosensor analysis. Current Opinion in Biotechnology
  14. (1998). All-atom empirical potential for molecular modeling and dynamics studies of proteins.
  15. (2004). Aminomethylpyrimidines as novel DPP-IV inhibitors: A 105-fold activity increase by optimization of aromatic substituents.
  16. (2000). an emergent ATPase/kinase superfamily.
  17. (1996). An experimental approach to mapping the binding surfaces of crystalline proteins.
  18. (1997). An integral equation to describe the solvation of polar molecules in liquid water.
  19. (1997). Analysis of temperature factor distribution in high-resolution protein structures. Protein Science
  20. and the chaperoning of cancer.
  21. (2006). Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors.
  22. (2007). Application of fragment screening by X-ray crystallography to beta-secretase.
  23. (2002). Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angewandte Chemie-International Edition
  24. (1999). Asparagine and glutamine: Using hydrogen atom contacts in the choice of side-chain amide orientation.
  25. (2004). Assessing scoring functions for protein-ligand interactions.
  26. Atomistic Models and Force-fields.
  27. (2009). Binding of Small-Molecule Ligands to Proteins: "What You See" Is Not Always "What You Get". Structure
  28. (1999). BLEEP—potential of mean force describing protein–ligand interactions: I. Generating potential.
  29. (1997). C-H...O Hydrogen Bonds in β-sheets. Acta Crystallographica Section D
  30. (2002). C-H···O Hydrogen Bonds in the Nuclear Receptor RAR[gamma]--a Potential Tool for Drug Selectivity. Structure
  31. (1991). Calorimetric determination of the enthalpy change for the alphahelix to coil transition of an alanine peptide in water. PNAS
  32. Calorimetry as a tool for understanding biomolecular interactions and an aid to drug design.
  33. (2005). CH...O and CH...N hydrogen bonds in ligand design: A novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor.
  34. (2005). CH...O and other weak hydrogen bonds. From crystal engineering to virtual screening. Chemical Communications
  35. (1998). CH...O hydrogen bond involving proline residues in alpha-helices.
  36. (2004). CH...O hydrogen bonds in protein-ligand complexes: Strong and weak interactions in molecular recognition. Proteins-Structure Function and Genetics
  37. (2000). Characterization of aromaticamide(side- chain) interactions in proteins through systematic ab initio calculations and data mining analyses.
  38. (2004). Characterization of Persistent Intramolecular
  39. (2009). CHARMM: The Biomolecular Simulation Program.
  40. (2008). Cl-pi interactions in proteinligand complexes.
  41. (2000). Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding.
  42. (2009). Combining Hit Identification Strategies: Fragment-163 Based and in Silico Approaches to Orally Active 2-Aminothieno 2,3-d pyrimidine Inhibitors of the Hsp90 Molecular Chaperone.
  43. (1996). Comparison of experimental and computational functional group mapping of an RNase A structure: Implications for computer-aided drug design. Protein Engineering
  44. (1996). Computational combinatorial ligand design: Application to human alpha-thrombin.
  45. (2002). Computational mapping identifies the binding sites of organic solvents on proteins.
  46. (2005). Computational Modeling Approaches to Structure-Function Analysis of G Protein-Coupled Receptors. Chemical Reviews
  47. (2005). Conformational changes observed in enzyme crystal structures upon substrate binding.
  48. (1992). Conformational studies on vancomycin using QUANTA-CHARMM. In
  49. (2010). Continuum Electrostatics Solvent Modeling with the Generalized B orn Model. In Modeling Solvent Environments Applications to Simulations of Biomolecules,
  50. (1993). Contribution of hydration to protein-folding thermodynamics .1. The enthalpy of hydration.
  51. (1992). Contribution of hydrogenbonding to the conformational stability of ribonuclease-t1. Biochemistry
  52. (2006). Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex. Nature
  53. (2003). Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nature Structural Biology
  54. (2003). Deficiency of the Coulomb-field approximation in the generalized Born model: An improved formula for Born radii evaluation.
  55. derivatives as a novel class of potent, selective, and orally active inhibitors of p38 alpha MAP kinase.
  56. (2009). Detection of ligand binding hot spots on protein surfaces via fragmentbased methods: application to DJ-1 and glucocerebrosidase.
  57. (2008). Development and application of Hsp90 inhibitors. Drug Discovery Today
  58. (1997). Development and validation of a genetic algorithm for flexible docking.
  59. (1988). Differential Binding of Peptide-Analog Inhibitors to Porcine Pancreatic Elastase. Abstracts of Papers Chemical Congress of North America
  60. (2007). Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.
  61. (2008). Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
  62. (2005). Do all backbone polar groups in proteins form hydrogen bonds? Protein Science
  63. (2008). Do enthalpy and entropy distinguish first in class from best in class? Drug Discovery Today
  64. (2002). Effective Born radii in the generalized Born approximation: The importance of being perfect.
  65. (2001). Efficient electrostatic solvation model for protein-fragment docking. Proteins-Structure Function and Genetics
  66. (2004). Efficient evaluation of binding free energy using continuum electrostatics solvation.
  67. (1997). Empirical scoring functions .1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.
  68. (2002). Energetics of a model NH-pi interaction: the gas phase benzene-NH3 complex. Physical Chemistry Chemical Physics
  69. (1999). Exhaustive docking of molecular fragments with electrostatic solvation. Proteins-Structure Function and Genetics
  70. (2001). Experimental and computational mapping of the binding surface of a crystalline protein. Protein Engineering
  71. (2006). Exploring the environmental preference of weak interactions in (alpha/beta)(8) barrel proteins. Proteins-Structure Function and Bioinformatics
  72. (1991). Extracting Hydrophobic Free Energies from Experimental Data - Relationship to Protein Folding and Theoretical Models. Biochemistry
  73. (2004). Fragment-based drug discovery.
  74. (2001). Fragment-based flexible ligand docking by evolutionary optimization.
  75. (2009). Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics
  76. (2009). Fragment-based Identification of Hsp90 Inhibitors. Chemmedchem
  77. (2005). Fragment-based lead discovery using X-ray crystallography.
  78. (2009). Fragment-based ligand discovery. Molecular Interventions
  79. (2005). Fragonomics: fragment-based drug discovery.
  80. (2001). Functional group placement in protein binding sites: a comparison of GRID and MCSS.
  81. (1991). Functionality Maps Of Binding-Sites - A Multiple Copy Simultaneous Search Method. Proteins-Structure Function and Genetics
  82. (2000). Highly Organized Spherical Hosts That Bind Organic Guests in Aqueous Solution with Micromolar Affinity: Microcalorimetry Studies. Chemistry – A European Journal
  83. (1994). HOOK: A Program for Finding Novel Molecular Architectures That Satisfy the Chemical and Steric Requirements of a Macromolecule Binding Site. Proteins: Structure, Function and Genetics
  84. (2006). hsp90: Twist and Fold. Cell
  85. (1996). Hydrogen bonding stabilizes globular proteins.
  86. (2003). Hydrogen Bonds in Protein-Ligand Complexes. In Protein-Ligand Interactions: From Molecular Recognition to Drug
  87. (2010). Hydrogen Bonds in Proteins: Role and Strength.
  88. (2001). Hydrogen bonds with pi-acceptors in proteins: Frequencies and role in stabilizing local 3D structures.
  89. (1985). Hydrogen-bonding and biological specificity analyzed by protein engineering.
  90. (1984). Hydrogen-bonding in globular-proteins.
  91. (2000). Identification of novel inhibitors of urokinase via NMR-based screening.
  92. (2003). Identification of substrate binding sites in enzymes by computational solvent mapping.
  93. (2005). Improving implicit solvent simulations: a Poisson-centric view.
  94. (2002). Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha.
  95. (2003). Interactions with aromatic rings in chemical and biological recognition. Angewandte Chemie-International Edition
  96. (1971). Interpretation of protein structures - estimation of static accessibility.
  97. (2008). Investigation of MMPBSA rescoring of docking poses.
  98. (1997). IsoStar: A library of information about nonbonded interactions.
  99. (2002). Kinase inhibitors and the case for CH...O hydrogen bonds in protein-ligand binding. Proteins-Structure Function and Genetics
  100. (2004). Letter to the Editor: <sup>1</sup>H, <sup>15</sup>N and <sup>13</sup>C resonance assignments of the apo Sm14-M20(C62V) protein, a mutant of <i>Schistosoma mansoni</i>
  101. (2009). Library screening by fragment-based docking.
  102. (2009). Ligand Mapping on Protein Surfaces by the 3D-RISM Theory: Toward Computational Fragment-Based Drug Design.
  103. (1995). LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions.
  104. (1996). Locating and characterizing binding sites on proteins.
  105. (1999). Locating interaction sites on proteins: The crystal structure of thermolysin soaked in 2% to 100% isopropanol. Proteins-Structure Function and Genetics
  106. (1993). Lost hydrogen-bonds and buried surface-area - rationalizing stability in globular-proteins.
  107. (2004). Medicinal chemistry in academia: molecular recognition with biological receptors.
  108. (2008). MM-GB/SA rescoring of docking poses in structure-based lead optimization.
  109. (2008). Modest stabilization by most hydrogen-bonded side-chain interactions in membrane proteins.
  110. (2009). Molecular docking and ligand specificity in fragmentbased inhibitor discovery.
  111. (2002). Molecular Driving Forces: Statistical Thermodynamics in Chemistry and Biology.
  112. (2010). Molecular fields in drug discovery: getting old or reaching maturity? Drug Discovery Today
  113. (2001). Molecular Modelling: Principles and Applications.
  114. (1993). Multiple copy simultaneous search and construction of ligands in binding sites - application to inhibitors of HIV-1 aspartic proteinase.
  115. (2006). Multiple solvent crystal structures: Probing binding sites, plasticity and hydration.
  116. (2005). mutagenic, and kinetic analysis of the binding of substrates and inhibitors of human phenylethanolamine N-methyltransferase.
  117. (2003). New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations.
  118. (2003). New analytical approximation to the standard molecular volume definition and its application to generalized Born calculations.
  119. (2004). Novel scoring functions comprising QXP, SASA, and protein side-chain entropy terms.
  120. (2003). On the nonpolar hydration free energy of proteins: Surface area and continuum solvent models for the solutesolvent interaction energy.
  121. (2000). Origin of the attraction and directionality of the NH/pi interaction: Comparison with OH/pi and CH/pi interactions.
  122. (2006). Overcoming roadblocks in lead optimization: A thermodynamic perspective.
  123. (1998). pi-stacking interactions - Alive and well in proteins.
  124. (2000). Predicting binding modes, binding affinities and 'hot spots' for protein-ligand complexes using a knowledge-based scoring function.
  125. (2003). Prediction of Non-bonded Interactions in Drug Design. In Proteinligand Interactions: From Molecular Recognition to Drug
  126. (1999). Probing the binding of indolactam-V to protein 173 kinase C through site-directed mutagenesis and computational docking simulations.
  127. (2003). Propensities, probabilities, and the Boltzmann hypothesis. Protein Science
  128. (2000). Protein thermal stability: insights from atomic displacement parameters (B values). Protein Engineering
  129. (2006). Protein-ligand binding affinity predictions by implicit solvent simulations: A tool for lead optimization?
  130. (2010). Protein-Ligand Interactions: General Description. In Encyclopedia of Life Sciences,
  131. (2001). Protein–Ligand Interactions:Molecular Basis. In Encyclopedia of Life Sciences,
  132. (1999). Rapid empirical scoring functions in virtual screening applications.
  133. (2004). Recent advances in the development and application of implicit solvent models in biomolecule simulations. Current Opinion in Structural Biology
  134. (2008). Recent developments in fragment-based drug discovery.
  135. (2003). Relibase: Design and development of a database for comprehensive analysis of protein-ligand interactions.
  136. (2006). SAR by NMR: Putting the pieces together. Molecular Interventions
  137. (1994). Satisfying hydrogen-bonding potential in proteins.
  138. (1996). scope, parameterization, and performance of MMFF94.
  139. (2004). Scoring functions for protein-ligand interactions: a critical perspective. Drug Discovery Today: Technologies
  140. (2007). SCORING FUNCTIONS: From Free-energies of Binding to Enrichment in Virtual screening.
  141. (2000). Side-chain flexibility in proteins upon ligand binding. Proteins-Structure Function and Genetics
  142. (2005). Simulating nucleic acids: Towards implicit and hybrid solvation models.
  143. (1994). Solvent Structure and Perturbations
  144. (2006). Structural Analysis of E. coli hsp90 Reveals Dramatic Nucleotide-Dependent Conformational Rearrangements. Cell
  145. (2001). Structural analysis of NSAID binding by prostaglandin H-2 synthase: Time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry
  146. (2003). Structural basis for the specificity of the nitric-oxide synthase inhibitors W1400 and N-omega-propyl-L-Arg for the inducible and neuronal isoforms.
  147. (1984). Structure of Bovine Pancreatic Trypsin-Inhibitor - Results of Joint Neutron and X-Ray Refinement of Crystal Form-II.
  148. (2003). Structure of the Nterminal domain of GRP94 - Basis for ligand specificity and regulation.
  149. (2001). SuperStar: Comparison of CSD and PDB-based interaction fields as a basis for the prediction of protein-ligand interactions.
  150. (1998). Synthesis and anticholinesterase activity of huperzine A analogues containing phenol and catechol replacements for the pyridone ring.
  151. (2004). Synthesis and In Vitro Evaluation of 2-Aminoquinazolin-4(3H)-one-Based Inhibitors for tRNA-Guanine Transglycosylase (TGT). Helvetica Chimica Acta
  152. (2008). Target Flexibility: An Emerging Consideration in Drug Discovery and Design.
  153. (2002). The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallographica Section B-Structural Science
  154. (2008). The importance of CH/[pi] hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase.
  155. (2000). The Magnitude of the CH/pi Interaction between Benzene and Some Model Hydrocarbons.
  156. (2009). The multi-copy simultaneous search methodology: a fundamental tool for structure-based drug design.
  157. (2009). The multiple roles of computational chemistry in fragment-based drug design.
  158. (1995). The Occurrence of CH...O Hydrogen Bonds in Proteins.
  159. (2008). The Open Babel Chemical File Format Conversion Package,
  160. (1951). The Pleated Sheet, A New Layer Configuration of Polypeptide Chains.
  161. (2000). The Protein Data Bank and the challenge of structural genomics.
  162. (2007). The Role and Significance of Unconventional Hydrogen Bonds
  163. (1993). The Role of Aromatic Rings as Hydrogen-Bond Acceptors in Molecular Recognition.
  164. The role of the methyl group in stabilising the weak N-H[small pi] hydrogen bond in the 4-fluorotoluene-ammonia complex.
  165. (1951). The Structure of Proteins: Two Hydrogen-Bonded Helical Configurations of the Polypeptide Chain.
  166. (2006). Thermodynamic Penalty Arising from Burial of a Ligand Polar Group Within a Hydrophobic Pocket of a Protein Receptor.
  167. (2004). Thermodynamics of protein-ligand interactions: History, presence, and future aspects.
  168. (1998). Three-dimensional density profiles of water in contact with a solute of arbitrary shape: A RISM approach.
  169. (2008). Towards an integrated description of hydrogen bonding and dehydration: Decreasing false positives in virtual screening with the HYDE scoring function. Chemmedchem
  170. (2009). Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discovery Today
  171. (2003). Understanding binding affinity: A combined isothermal titration calorimetry/molecular dynamics study of the binding of a series of hydrophobically modified benzamidinium chloride inhibitors to trypsin.
  172. (2008). Understanding ligand-based modulation of the Hsp90 molecular chaperone dynamics at atomic resolution.
  173. (2002). Unusually long cooperative chain of seven hydrogen bonds. An alternative packing type for symmetrical phenols. Chemical Communications
  174. (1997). Use of the multiple copy simultaneous search (MCSS) method to design a new class of picornavirus capsid binding drugs. Proteins-Structure Function and Bioinformatics
  175. (2004). Validation of an empirical RNA-ligand scoring function for fast flexible docking using RiboDock (R).
  176. (2001). Very empirical treatment of solvation and entropy: a force field derived from Log P-o/w.
  177. (1977). Volumes, Packing, and Protein Structure. Annual Review of Biophysics and Bioengineering
  178. (2001). Water at hydrophobic surfaces: Weak hydrogen bonding and strong orientation effects. Science
  179. (2007). water everywhere - except where it matters? Drug Discovery Today
  180. (1999). Weak Hydrogen Bond in Structural Chemistry and Biology.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.